Sanofi: Dupixent® (dupilumab) showed positive topline results in two Phase 3 trials of patients with chronic rhinosinusitis with ...
Dupixent® (dupilumab) showed positive topline results in two Phase 3 trials of patients with chronic rhinosinusitis with nasal polyps Dupixent significantly reduced nasal polyp size, nasal congestion severity, and need for systemic corticosteroids and/ …